Hiroji Uemura1, Nobuaki Matsubara2, Go Kimura3, Akito Yamaguchi4, Dianne Athene Ledesma5, Marco DiBonaventura6, Ateesha F Mohamed7, Enrique Basurto6, Ian McKinnon6, Ed Wang7, Kristen Concialdi6, Aya Narimatsu5, Yasuko Aitoku8. 1. Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan. 2. Division of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan. 3. Department of Urology, Nippon Medical School, Tokyo, Japan. 4. Division of Urology, Harasanshin General Hospital, Fukuoka, Japan. 5. Bayer Yakuhin, Ltd., 2-4-9, Umeda, Kita-ku, Osaka, 530-0001, Japan. 6. Kantar Health, New York, NY, USA. 7. Bayer Healthcare, Whippany, NJ, USA. 8. Bayer Yakuhin, Ltd., 2-4-9, Umeda, Kita-ku, Osaka, 530-0001, Japan. yasuko.aitoku@bayer.com.
After publication of this work [1] it was noticed that there was a typographical error in the Conclusions. The letter ‘a’ in ‘asymtoptomatic’ should have been removed in the concluding statement as it is inconsistent with the Results and Discussion. The statement in the Conclusions should read: ‘Patients who were symptomatic placed significantly more importance on delaying an SSE when expressing medication preferences.’The original article was corrected. The publisher apologises for this error.